Document Detail


Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
MedLine Citation:
PMID:  12525519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The most recent and powerful prognostic instrument established for myelodysplastic syndromes (MDS) is the International Prognostic Scoring System (IPSS), which is primarily based on medullary blast cell count, number of cytopenias, and cytogenetics. Although this prognostic system has substantial predictive power in MDS, further refinement is necessary, especially as far as lower-risk patients are concerned. Histologic parameters, which have long proved to be associated with outcome, are promising candidates to improve the prognostic accuracy of the IPSS. Therefore, we assessed the additional predictive power of the presence of abnormally localized immature precursors (ALIPs) and CD34 immunoreactivity in bone marrow (BM) biopsies of MDS patients. PATIENTS AND METHODS: Cytogenetic, morphologic, and clinical data of 184 MDS patients, all from a single institution, were collected, with special emphasis on the determinants of the IPSS score. BM biopsies of 173 patients were analyzed for the presence of ALIP, and CD34 immunoreactivity was assessable in 119 patients. Forty-nine patients received intensive therapy. RESULTS: The presence of ALIP and CD34 immunoreactivity significantly improved the prognostic value of the IPSS, with respect to overall as well as leukemia-free survival, in particular within the lower-risk categories. In contrast to the IPSS, both histologic parameters also were predictive of outcome within the group of intensively treated MDS patients. CONCLUSION: Our data confirm the importance of histopathologic evaluation in MDS and indicate that determining the presence of ALIP and an increase in CD34 immunostaining in addition to the IPSS score could lead to an improved prognostic subcategorization of MDS patients.
Authors:
E Verburgh; R Achten; B Maes; A Hagemeijer; M Boogaerts; C De Wolf-Peeters; G Verhoef
Related Documents :
17342649 - Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an ob...
10678699 - Large plaque parapsoriasis: clinical and genotypic correlations.
2386769 - Detection of residual bcr/abl transcripts in chronic myeloid leukaemia patients in comp...
18004179 - Management of hypereosinophilic syndrome: a prospective study in the era of molecular g...
7947269 - Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia ...
14965169 - Hairy cell leukemia: an autopsy study.
12032369 - A pilot study comparing percutaneous decompression with decompressive laparotomy for ac...
23383749 - Screening colonoscopy in liver transplant candidates: risks and findings.
12464339 - Observations on intraoperative somatosensory evoked potential (sep) monitoring in the s...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  21     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-01-14     Completed Date:  2003-02-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  273-82     Citation Subset:  IM    
Affiliation:
Department of Hematology, University Hospitals, University of Leuven, Leuven, Belgium. estelle.verburgh@uz.kuleuven.ac.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD34 / metabolism
Bone Marrow / metabolism,  pathology*
Child
Cytogenetic Analysis
Female
Humans
Immunoenzyme Techniques
Karyotyping
Male
Middle Aged
Myelodysplastic Syndromes / classification,  diagnosis*,  metabolism
Neoplasm Staging
Prognosis
Risk Factors
Survival Rate
Chemical
Reg. No./Substance:
0/Antigens, CD34

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Gro...
Next Document:  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or re...